OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-06-30-accounts

Better lung health for all

The British Thoracic Society

Annual Report and Financial Statements for the year ended 30 June 2025

Company Number: 1645201, Charity Number: 285174, OSCR Number: SC041209

BTS Annual Report 2024/25

Table of Contents

CHAIR’S FOREWORD ...................................................................................................................................... 3 OUR STRATEGY AND PURPOSE ...................................................................................................................... 5 HOW OUR ACTIVITIES DELIVER PUBLIC BENEFIT ........................................................................................... 6 STANDARDS, WORKFORCE AND EDUCATION ................................................................................................ 8 RESEARCH AND INNOVATION ...................................................................................................................... 11 PROFILE ......................................................................................................................................................... 12 THE BTS HEAD OFFICE TEAM ........................................................................................................................ 13 FINANCIAL REVIEW ....................................................................................................................................... 15 STRUCTURE, GOVERNANCE AND MANAGEMENT ....................................................................................... 17 STATEMENT OF RESPONSIBILITIES OF TRUSTEES ......................................................................................... 21

The Trustees of the British Thoracic Society (BTS) present our report and the audited financial statements for the year ended 30 June 2025. The reference and administrative information set out on page 22 forms part of this report.

The financial statements comply with the Charities Act 2011; the Companies Act 2006; the Memorandum and Articles of Association; and the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

2

BTS Annual Report 2024/25

CHAIR’S FOREWORD

It gives me great pleasure to present this year’s Annual Report on behalf of the British Thoracic Society (BTS).

Over the past year, our community has continued to demonstrate remarkable resilience, innovation and commitment to improving respiratory health across the UK and beyond. Despite the ongoing pressures on our health system, the Society has remained steadfast in its mission: to drive excellence in the prevention, diagnosis, treatment, and care of people with respiratory disease and to achieve our mission statement of “better lung health for all”.

We have expanded our programme of clinical guidelines and quality standards, ensuring that respiratory care remains evidence-based, equitable, and centred on patients’ needs. Our educational offerings have grown significantly, reaching more members than ever before and supporting professionals at every stage of their careers. Collaboration with our partners across the NHS, academia, industry, and patient organisations has continued to flourish, strengthening the collective voice of respiratory medicine.

Here are some key numbers: membership has increased by 20% over 4 years (from 4109 to 4911), short course attendance has increased from 735 delegates in 10 courses to 1093 in 12. Summer Meeting numbers are up from 600 to 712.

Our flagship Winter Meeting goes from strength to strength. We now fill the QEII Centre, and the numbers attending increase year-on-year, as does the number of abstract submissions. This Meeting will be a key driver in increasing the visibility and impact of BTS and attracting new members.

The engagement with you, our members, increases with more colleagues than ever applying for BTS positions. This is a sign of good health for the Society, and both encourages and demands a response from the BTS officers and staff.

This year has also been one of renewal and forward planning. We are investing in digital transformation, new approaches to member engagement, and the development of resources that will sustain the Society’s impact for years to come, with a new website being the cornerstone of this. Importantly, we remain committed to supporting research, advocacy, and policy initiatives that address health inequalities and ensure that respiratory disease receives the attention it urgently requires. The Society is in a strong place, and we cannot stand still. We will be proactive in the

3

BTS Annual Report 2024/25

current unstable environment. These times are an opportunity for the Society to be more relevant than ever.

None of these achievements would be possible without the dedication of our members, the energy of our committees, and the support of our staff team. I would like to extend my sincere thanks to each of you for your contribution to the Society and to the patients and communities we serve.

It is also implicit in this report the part played by the Society’s staff. All we do and achieve is made possible by the head office team, who are remarkable both as individuals and as a collective. Their work has been disrupted by the substantial building works, which they have seamlessly worked around. I owe them all a personal debt of gratitude.

As we look ahead, we do so with optimism and determination. The challenges in respiratory health are great, but so too are the opportunities to make a lasting difference. Together, we will continue to shape the future of respiratory care and champion the highest standards of practice. I encourage you to read this report and please feedback to myself or any of the BTS team. This is your Society, and I would like you to be proud of being a member, to enjoy being a member and feel that what the Society does is of relevance to you and to all working in respiratory disease.

Professor Richard Russell

Chair of the BTS Board of Trustees

4

BTS Annual Report 2024/25

OUR STRATEGY AND PURPOSE

The Society published strategic priorities in 2022/23 for the period 2023-2025.

Our Vision

Better lung health for all.

Our Mission

Our strategic priorities for 2023 – 2025

The outcomes we intend to achieve are set out as follows:

To represent the entire multi-professional respiratory team across the four nations.

Outcome: We will continue to work with stakeholders to provide an expert and authoritative voice to champion the role, expansion, and impact of the respiratory workforce to ensure that everyone has access to high quality respiratory care from the right person, at the right time, in the right setting.

To deliver education and continued professional development to the entire multi-professional respiratory team.

Outcome: We will work to engage, encourage, and support all members of the respiratory team by providing high quality education and networking opportunities that are relevant at all stages of an individual’s career.

To support the development and delivery of high-quality respiratory care which encompasses disease prevention, early diagnosis, therapeutic intervention, and supportive care.

Outcome: We will continue to improve standards of care for patients and reduce health inequalities via our internationally recognised scientific meetings, our journals and our programme of evidencebased guidance, standards, and position statements.

To ensure BTS remains a well-governed, inclusive, and financially stable membership organisation.

Outcome: We will continue to represent and involve the growing multi-professional respiratory team in the work of the Society, underpinned by a strong and transparent business model.

5

BTS Annual Report 2024/25

Annual review

The Board reviews progress against the strategic priorities each year and this Report provides an account of the Society’s activities undertaken to meet the outcomes specified above. This helps Trustees to make sure that the Society’s aims, objectives, and activities remain focused on its stated purposes. This report sets out how the Society has worked to deliver its mission during the 20242025 year.

HOW OUR ACTIVITIES DELIVER PUBLIC BENEFIT

The Society produces a range of information, publications, clinical standards , and related resources which are freely available to all via the BTS website and the Respiratory Futures website. Health care professionals are able to use these resources to improve practice locally, which in turn benefits patients in their care. Our communications activities ensure that these resources are brought to the widest possible audience, including policy makers and the public.

BTS conferences and events attract a wide audience of health care professionals from all members of the respiratory team. Our events ensure that those attending obtain maximum benefit from both face-to-face opportunities to develop networks, as well as the flexibility that online attendance offers for some events.

Workforce remains a key priority for the Society. BTS has continued to work to raise the profile and importance of respiratory health care professionals.

Following the publication of the BTS Position Statement on Sustainability and the Environment: Climate Change and Lung Health in 2024, the Society is working on the development of a toolkit to support respiratory healthcare professionals. The Society has continued to highlight the link between air quality and lung health . BTS is a full member of the UK Health Alliance on Climate Change and the Healthy Air Coalition.

BTS continues to work to meet the stated aims of its Inclusion, Diversity and Equality policy published in 2021. A specific focus of this work during the year has been the support of women working in respiratory .

Highlighting health inequalities and the impact that this has on respiratory patients continues to be a theme of the Society’s work, building on the publication of the BTS Position Statement in 2023.

BTS was pleased to welcome two new lay trustees to the Board in November 2024, Ms Lucy Davies and Ms Caroline Nokes.

BTS, through Respiratory Futures, launched a new Podcast series which explores breakthroughs and provides first-hand accounts from leading experts who work at the forefront of respiratory healthcare and medicine.

The Trustees confirm they have referred to the guidance from the Charity Commission on public benefit and complied with the duty in Section 17 of the Charities Act 2011 to have due regard to the Commission's public benefit guidance. The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Society's aims and objectives and planning for future activities.

6

BTS Annual Report 2024/25

ACHIEVEMENTS AND PERFORMANCE

We describe our three main areas of activity in the Statement of Financial Activities (the SOFA) as follows.

Standards, workforce, and education

These activities are undertaken under the direction of the Society’s Standards of Care Committee; the Quality Improvement Committee; the Education and Training Committee; and the Workforce and Service Development Committee, together with the input of the Society’s Specialist Advisory Groups (SAGs), the Specialty Trainees Advisory Group (STAG), Nurse Advisory Group and Pharmacist Advisory Group.

Research and innovation

The Society achieves objectives in this area through the work of the Science and Research Committee, which oversees the annual Winter Meeting and provides strategic direction to the Society in relation to the support of respiratory research. The Society is a joint owner of the journals Thorax and BMJ Open Respiratory Research.

BTS is committed to working to promote and advance knowledge and awareness of lung health to the public, to healthcare professionals and to policymakers and government bodies. This is done pro-actively and reactively in partnership with other professional societies and lung charities, and via internal and external communications.

The Respiratory Futures platform, coupled with our strengthened communications team, allows us to reach a wider audience and to support the respiratory communications capacity within BTS Head

In July 2024, BTS launched a new podcast hosted by BTS Members and produced in-house by the Communications Team. The Respiratory Futures Podcast is a series which features leading experts in conversation about innovations and best practice in respiratory medicine, as well as discussion of related topics such as sustainability, data and coding. During the year 14 episodes of the podcast were recorded, attracting over 7650 downloads.

7

BTS Annual Report 2024/25

STANDARDS, WORKFORCE AND EDUCATION

Standards

Clinical Guidelines, Clinical Statements and Quality Standards

BTS published the following guidance documents during the year:

Work on a number of other guidelines, quality standards and clinical statements is underway.

To support the dissemination of our guidance, BTS hosted 4 webinars during this period. Over 560 people attended, drawn from the range of professions working in respiratory medicine and beyond.

BTS/NICE/SIGN Joint Guideline for the diagnosis, monitoring and chronic asthma management and the joint BTS/NICE/SIGN asthma pathway

Following a lengthy period of productive joint working, the BTS/NICE/SIGN Guideline for the diagnosis, monitoring and management of chronic asthma was published in November 2024 and was launched at a symposium at the 2024 BTS Winter Meeting. A recording of the symposium is available on the BTS website and has been viewed over 2,700 times. The guideline is available on the NICE website

The joint working arrangements also produced a collaborative asthma pathway , launched at the same time as the guideline, bringing all relevant BTS/NICE/SIGN guidance on asthma into one place. The pathway is available on both the NICE and the RDS (Right Decision Scotland) websites.

BTS delivered two webinars in March on both the adult and children/young people aspects of the guideline. Recordings of these webinars have been watched over 1000 times.

BTS and SIGN will continue to work together in future to refresh guidance on acute asthma and develop new clinical guidance on severe asthma.

UK ILD Registry

The UK Interstitial Lung Disease Registry launched in February 2023. Building on the existing BTS UK patient registries, the new Registry collects information about people diagnosed with ILD, including those affected by specific interstitial lung conditions. The 2025 Report on the UK ILD Registry was published in May.

There were just over 2240 new cases added to the UK ILD Registry between July 2024 and June 2025, with 10,835 cases on the Registry overall. ILD registry abstracts appeared as 4 publications during the year:

8

BTS Annual Report 2024/25

BTS Multi Drug-Resistant-Tuberculosis Clinical Advice Service

The MDR-TB Clinical Advice Service provides advice and support to clinicians who care for patients with MDR-TB, providing consensus expert advice from a multi-disciplinary panel of formally appointed Clinical Service Advisers. For the period July 2024-June 2025, there were a total of 224 cases discussed through the service, of which 208 were newly registered cases .

Clinical Audit Programme

New BTS clinical audit platform launched

In April 2025 the BTS clinical audit platform was relaunched, a culmination of 18 months of work to improve the experience of users using the platform, refresh the look and ensure that the audit platform is fit for purpose as a data collection tool for years to come.

National Respiratory Support Audit – reports published in 2024

Following the publication of the National Respiratory Support Audit report in June 2024, which captured data on over 4,100 patients receiving enhanced respiratory care across 115 hospitals, BTS hosted a webinar in December 2024. The webinar focused on the key findings of the report, which showed that acute patients seen in enhanced respiratory care facilities, such as Respiratory Support Units, had significantly lower mortality rates than those receiving care in regular wards.

Patient Safety

Analysing patient safety incident data in respiratory

Building on previous work to analyse respiratory-related patient safety incidents reported on the National Reporting and Learning System (NRLS), a paper on safety incidents in pleural procedures was published in March 2025. The review reported a range of patient safety concerns and highlighted the need for better training, improved ultrasound use, and clearer protocols. The findings of the report were published in a paper in BMJORR.

Work on the analysis of patient safety incidents in respiratory medicine, focusing initially on the use of oxygen in Type 2 respiratory failure, continues as part of the Quality Improvement Committee workstream.

NCEPOD study: pleural procedures

BTS was pleased to support the proposal for a National Confidential Enquiry into Patient Outcome and Death (NCEPOD) study which has been commissioned by the Healthcare Quality Improvement

9

BTS Annual Report 2024/25

Partnership. The review of pleural procedures aims to identify underlying factors contributing to procedural risks and to drive meaningful improvements.

Clinical Data Policy and Data Access

BTS provides access to its clinical datasets (Audit, Registry, MDR-TB Clinical Advice Service) subject to the appropriate approvals being granted. Organisations can make a formal application to BTS, which will be reviewed by the Quality Improvement Committee. In 2024/25, three data access requests were approved, of which two were for ILD registry data and one for MDR-TB data. The Society continues to promote data access to those who wish to use its comprehensive audit, Registry and MDRTB datasets.

Joint Tuberculosis Committee

BTS hosts this important group which comprises stakeholders from the four nations of the UK and works to ensure the exchange of information and good practice for the benefit of patients with Tuberculosis (TB). The Committee has played a key role in recent months in bringing together stakeholders to address gaps in TB guidance, implement the findings of the TB Getting it Right First Time report and co-ordinate a response to shortages in TB drug treatments.

Specialist Advisory Groups

Our network of 19 Specialist Advisory Groups continues to advise the Society on national matters relating to patients with specific types of respiratory disease. With SAG support, we have provided comment on 21 national consultation exercises.

Workforce

BTS published “ A Respiratory Workforce for the Future ” in May 2022. This document has since been downloaded from the BTS website 2456 times and has been used to support the Society in continued discussions with national leaders in relation to the respiratory workforce. BTS published a professional framework for Advanced Clinical Practitioners (ACPs) during the year. Work continues to develop a further two professional framework documents to support respiratory pharmacists, and those working in pulmonary rehabilitation.

Through the Workforce and Service Development Committee , the Society contributes to the work of the Respiratory Specialty Advisory Committee (SAC)/Joint Royal College Physicians Training Board (JRCPTB), the Royal Colleges of Physicians, and Regional Training Programme Directors.

The Workforce and Service Development Committee continued to oversee the Society’s data collection activities in relation to consultant and trainee posts, as well as raising the profile of the full respiratory team. The following activities took place during the year:

10

BTS Annual Report 2024/25

Education

The Society’s range of educational activities included:

RESEARCH AND INNOVATION

The Society publishes two journals in partnership with the British Medical Journal (BMJ) :

The BTS Winter Meeting remains the foremost inclusive respiratory conference in the UK, and undoubtedly one of the most influential conferences of its type globally, attracting a multi-disciplinary audience from the UK and several hundred delegates annually from Europe and more widely. In November 2024, the Winter Meeting attracted over 2697 delegates across three days of high-quality scientific presentation and debate. The Society awarded 29 conference awards to enable delegates to travel to the meeting to present abstracts.

BTS hosted a Respiratory Research Training Day in May 2025, providing a programme of information and advice about starting a respiratory research career for 40 respiratory specialty trainees.

The BTS Science and Research Committee provided four letters of support for applications for research proposals.

BTS is represented on the Lung Research and Innovation Group hosted by Asthma + Lung UK and has supported the launch of the Grand Challenges for respiratory research

BTS offers awards to recognise excellence in the field of respiratory research and clinical care: The BTS/A+LUK/BALR mid-career lecture awards, which provide researchers with the opportunity to give a prestigious plenary lecture at the Winter Meeting.

11

BTS Annual Report 2024/25

PROFILE

BTS Membership grew during the year, rising to 4911 in June 2025 compared to 4678 in June 2024. BTS has continued to promote the benefits of membership to all members of the respiratory team, and has seen the number of BTS members from the nursing and allied health care professions grow by over 20% over the past 4 years. Over 50% of BTS members are able to take advantage of the discounted membership rates for the European Respiratory Society.

BTS has enhanced and expanded its communications activities, supported by the new BTS communications team, aiming to raise the “respiratory voice” wherever the opportunity occurs. 140 pieces of coverage were placed, X followers grew from 32,455 to 33,120 across our @BTSRespiratory and @respfutures accounts, and LinkedIn followers grew from 3,226 to 4,612.

BTS continues to develop and maintain effective partnerships and relationships across the NHS and with stakeholder organisations to support and influence national and local policy. We respond to national calls for evidence in support of the NHS workforce and participate in discussion and meetings with national groups including the Royal Colleges and with from Wales, Northern Ireland and Scotland through BTS Council.

BTS is an active partner in the Taskforce for Lung Health , and with Asthma + Lung UK, takes the lead in the UK involvement in the International Respiratory Coalition .

BTS continues to maintain valued relationships with organisations including Asthma + Lung UK, the Association for Respiratory Technology and Physiology (ARTP), the Association of Respiratory Nurses (ARNS), the Association of Chartered Physiotherapists in Respiratory Care (ACPRC), Action for Pulmonary Fibrosis, the Primary Care Respiratory Society (PCRS), and the British Paediatric Respiratory Society (BPRS).

BTS was pleased to join with the Irish Thoracic Society and Ulster Thoracic Society to jointly host a meeting for over 100 respiratory health care professionals from Ireland and the 4 nations of the UK in Belfast in March 2025.

BTS continues to be an active member of UK Health Alliance on Climate Change (UKHACC), a collaboration of organisations working to raise the profile of climate change across healthcare and also the Healthy Air Coalition (HAC), a collective of health, environment and transport organisations. The publication of the BTS Position Statement on Sustainability and the Environment: climate change and lung health sets out the Society’s stance on how the impact of climate change and the carbon footprint of respiratory healthcare can be assessed, reduced and mitigated , and provides the starting point for further work in this area over the coming years. Our continued membership of the

12

BTS Annual Report 2024/25

Taskforce for Lung Health is one way of achieving this, as is our membership of the UK Health Alliance on Climate Change.

The BTS Global Lung Health Group has been reconstituted as a Task and Finish Group with a 3 year programme to explore how BTS can best support global lung health. The Group will be working over the coming months to develop a work plan.

BTS launched a new initiative, Women in Respiratory, which aims to support all women in every role across the respiratory team. A dedicated area of the Respiratory Futures website was launched at the 2025 Summer Meeting.

BTS was recognised by the Association Excellence Awards in 2024 by reaching the shortlist in two categories:

BTS published an updated Position Statement, which outlines the Society’s views on Tobacco and Vaping and emphasises its position that only clean air should be in the lungs . The Society was also pleased to support the Tobacco and Vapes Bill, which will develop legislation to prevent children who are 14 or younger from ever being legally sold tobacco, transforming the health of generations to come. BTS will continue to support the provision of tobacco dependence programmes across the four nations and join with stakeholders as part of the Smokefree Action Coalition to champion the prevention of smoking-related lung disease.

BTS HEAD OFFICE

The Society’s Senior Management Team comprises Sally Welham, Chief Executive, Rosie O’Carroll, Head of Strategic Communications, Louise Preston, Head of Strategic Programmes, Miguel Souto, Head of Clinical Programmes and Kathryn Wilson, Head of Operations. Shani Kennedy joined the Senior Management Team from March to September 2024 as maternity cover for Kathryn Wilson. The full list of BTS staff members is on page 23.

BTS would like to acknowledge and thank all the many respiratory healthcare professionals for their outstanding hard work, flexibility, resilience, and compassion.

The Society is proud to represent the respiratory community - we applaud all you have done and continue to do for your patients and for the health service.

13

Impact Summary 2024/25 This year there were...

4

Guidance Documents Published

National Consultations Responded To

248K

BTS/NICE/SIGN Asthma Guideline Downloads/Views

761 Summer Meeting Delegates

2,697 2024 Winter Meeting Delegates

560 Webinar Attendees

1,093 Short Course Delegates

430 Group & Committee Members

4,911 Members

5k[LinkedIn Followers] 33k[X/Twitter Followers] 7.6k Podcast Downloads

BTS Annual Report 2024/25

FINANCIAL REVIEW

Core costs

Trustees have approved deficit budgets for the last six financial years, 2019/20, to 2024/25 as a result of considered decisions taken since 2016 to support efforts to raise the respiratory profile. This has allowed the appointment of a number of new members of staff over the past 3 years to support activities overseen by the current Senior Management Team. Trustees still have no doubt that the Society remains a going concern.

We are fortunate to have robust income streams that support our core work. These are membership subscriptions, at £747,363 in 2025 compared to £715,842 in 2024. At the end of June 2025, we had 4,911 members (up from 4,678 in June 2024, and an increase of 1213 members since June 2020). The partner’s share of the profit from the journal Thorax and BMJ Open Respiratory Research is the other core income stream. Income from the journals decreased to £588,448 (compared to £631,755 in 2024, but an increase on the amounts in the previous 2 years, £540,259 in 2023, £565,044 in 2022). The Management Committee for the journals will continue to monitor the accounts for the journals closely over the coming year.

Investment Policy and Performance

Management of the BTS investment portfolio is undertaken by Evelyn Partners. The Society’s Investment Policy is reviewed annually by the Board each December and currently sets out a “Growth Strategy”, which

“…. appropriate for an investor with a five-year time horizon, who is comfortable with significant volatility of returns and having up to 80% of their portfolio in equities, and who is able to tolerate a loss of up to 20% of the value of the portfolio in any one year”.

Quarterly reports are received from the Investment Managers and bi-annual meetings are held between the investment managers and the Honorary Treasurer and Chief Executive to review progress and assess the approach to management of the funds. The Honorary Treasurer speaks to the Society’s dedicated Investment Manager before each meeting of the Board of Trustees in order to report on progress.

The Investment Policy . The instruction not to invest in the tobacco industry or tobacco-related products remains strictly in place. The Investment Policy was amended in 2016 to include the requirement that investments are not made in industries involved in the extraction of fossil fuels or in industries that make weapons. The Investment Policy was amended in early 2024 to reflect Board

15

BTS Annual Report 2024/25

agreement that there should be explicit instructions not to invest in companies whose principal business is the manufacture/sale of alcoholic beverages, as well as explicit instructions to consider the ethical practices of the companies in which they invest. In 2017 Trustees agreed to draw a proportion of the annual investment gain as income to support the Society’s activities.

Reserves

Total funds at 30 June 2025 were £7,216,216 (£7,485,748 in 2024, £7,146,926 in 2023) comprising restricted funds of £20,000 (£106,611 in 2024) and unrestricted funds of £7,196,216 (£7,379,137 in 2024).

The Society holds reserves for two purposes. The first is to generate income for its operational needs (the investment reserve). This is held as a designated fund and stands at £4,689,318 (£4,892,440 in 2024, £4,662,672 in 2023, and £4,386,259 in 2022). The second purpose is to ensure that the Society can meet its operational needs and working capital requirements (the free reserve). The free reserve is represented by the general fund: this stands now at £874,630 (£881,212 in 2024, £782,610 in 2023, and £741,607 in 2022). At the November 2022 meeting of the Board, it was agreed that the reserve policy should be amended and maintained in future at a level equivalent to between three and six months, or 25-50% of projected expenditure based on that year’s budget, with the Society holding a minimum of three months, or 25%, projected expenditure.

Funds

Interest & Investment income earned has been attributed to individual funds in the ratio of the fund balance to total funds.

16

BTS Annual Report 2024/25

STRUCTURE, GOVERNANCE AND MANAGEMENT

The British Thoracic Society (“the Society”/ “BTS”) is a charitable company limited by guarantee which has no share capital. It was incorporated on 21 June 1982 and registered as a charity on 21 June 1982. The Office of the Scottish Charity Regulator (OSCR) approved the Society’s application to be registered as a charity in Scotland in early 2010.

As a registered charity, the Society is governed by its Memorandum and Articles of Association. Trustees review these regularly. The most recent revisions were approved by the Charity Commission in December 2016. The document can be viewed at Governance Documents and Policies | British Thoracic Society | Better lung health for all

Board of Trustees

The Board comprises five honorary officer positions; the Chairs of the Society’s main (Standing) Committees; and up to three others, chosen by the Board for their particular expertise in relevant areas according to the requirements of the Society’s Strategic Plan. A list of all Trustees who served during the year and up to the date this Report was approved appears on page 22.

The Board provides strategic decision-making and direction for those who are responsible for delivering the Society’s operations and activities. The normal term in office for Trustees is three years, as it is for all who serve on BTS Committees and Advisory Groups. All Trustees are made aware of relevant Charity Commission and Companies House Guidance on appointment and are required to undertake induction training provided by the Society’s lawyers and senior staff. In accordance with the Society’s constitution, the Chair, Honorary Secretary and Honorary Treasurer are selected up to a year in advance of taking up their posts, to allow some shadowing to take place. An induction programme is provided to the three Honorary Officers in the months before they take up post, and they usually start to attend meetings of the Board of Trustees and Council in the autumn of the year they assume office.

BTS Council

The Society’s Council has a significant role. It comprises 18 elected members plus the President (who chairs meetings of the Council), the Chair of the Board of Trustees and several ex-officio appointments, including the Chairs of the BTS Specialty Trainees Advisory Group and the BTS Nurse Advisory Group, the British Paediatric Respiratory Society, British Association of Lung Research and Asthma + Lung UK (formerly the British Lung Foundation). Elections take place annually for 6 new Council members. The Council’s constitution was amended during the year to remove the requirement for one member under the age of 35 to be elected each year. The following clause was approved following the AGM in November 2024: there will be one member elected each year who “shall either be doctors in training, or nurses/allied health professionals who are within 10 years of their primary respiratory qualification, at the time of election”.

Council acts as a sounding board for Society policies and a guide for Trustees about general membership opinion. Bi-annual meetings of Council are timed to take place in the mornings before Trustees meet, so that related operational decisions can be made quickly and effectively. Topics covered during the year included the revision of the Society’s position statement on tobacco and vaping, discussion on the support of respiratory research and an increased focus on engagement with thoracic society leadership from Scotland, Wales and Northern Ireland.

17

BTS Annual Report 2024/25

Standing Committees and Specialist Advisory Groups (SAGs)

These important groups enable the Society to organise and deliver core work programmes (the Standing Committees) and communicate quickly and efficiently with expert opinion when required (the Committees and Advisory Groups). Senior staff ensure that the agendas of the Board and Standing Committees are aligned with a focus on how the work of the latter contribute to the Society’s overall strategy, allowing sufficient space for discussion and approval by Trustees of annual work plans of the main Committees. A clear constitution for each Committee and a common constitution for all SAGs ensures regular and planned turnover of members and consistent methods of operation. Separate constitutions exist for the Nurse Advisory Group, Pharmacist Advisory Group and Specialty Trainee Advisory Group. The SAG Chairs meet Trustees once a year to discuss strategic and operational matters, and each provides a written report. Each SAG holds an Open Meeting during the Society’s Winter Meeting to report to BTS members and others about their activities and to seek feedback.

A recruitment round for new members of Committees and SAGs takes place each June – August (of the order of 70 vacancies), as well as recruitment of the President-Elect and any other Officer or Trustee roles that fall due.

Involving the public, patients and carers

In 2023, the Board agreed to develop an overall policy framework to ensure the way the Society includes the voice of patients, carers, and the public is meaningful and effective. The framework was published in 2023 and sets out how the Society brings the patient, carer and public voice appropriately to the way in which the Society is governed, the work it does and how the Society works with others. Two new lay trustees were appointed to the BTS Board in November 2024.

Member Engagement and Involvement

The Society’s Strategic Plan mentions that one of the ways by which the Society expects to achieve its objectives is by harnessing the expertise and commitment of its members. The Society had 4,911 members at the end of June 2025, (4,678 in 2024, 4,480 in 2023, 4,254 in 2022, 4,109 in 2021, 3,778 in 2020, 3,349 in 2019 and 3,049 in 2018). 430 members, around 10 % of UK-based members, were engaged in and/or working on BTS projects or in BTS Committees and Advisory and Guideline Groups during the year. They are listed in Appendix A, and we wish to record our thanks and gratitude to all of them. We are proud of this level of engagement, which is supported by a robust and democratic framework of access to membership of Committees and Specialist Advisory Groups (SAGs).

Operational Framework

The Trustees are responsible for all strategic and some of the operational decisions taken by the Society. These include allocation of resources in pursuit of the objectives within the Strategic Plan, although the majority of the latter decisions are devolved to the Officers’ Group and most operational decisions are delegated to the Chief Executive and the Senior Management Team.

Standing Financial Instructions exist in relation to decision-making about ordering of goods and services, for authorising expenditure and for authorised signatories on the Society’s accounts.

18

BTS Annual Report 2024/25

These instructions are reviewed annually by the Chief Executive and Honorary Treasurer, at the time of the annual audit. There are three authorised signatories on the BTS accounts (Chief Executive, Honorary Treasurer and Chair of the Board). There is also clear separation of duties in respect of staff roles and responsibilities for financial activities. The “Items of Reserved Business” statement within the Standing Financial Instructions gives details about what decisions must always be discussed in full by all Trustees, and what can be deferred to the Officers’ Group and/or senior staff. From 2020, the Officers Group has also performed the role of Internal Audit Committee and receive and consider the annual report from the auditors.

Accounting

The Board considers quarterly management accounts and reports at each of its four meetings during the year, with narrative provided by the Honorary Treasurer and Chief Executive. The narrative focuses on reasons for variation against budget. Operational decisions that might be needed in the meantime are discussed by the five Honorary Officers and Chief Executive, who usually meet monthly (via Teams) and more frequently when required (weekly or fortnightly meetings were held during the peak of the pandemic). Annual budgeting is the responsibility of the Chief Executive and the Society’s accountants, with bi-annual review (at the half -year and end of each financial year). Indicative budgets are prepared for the following two years, and the Chief Executive and Honorary Treasurer will review closely at least once a year prior to the year end.

Remuneration

The Society established a Remuneration Committee in 2007, which reports to the Board. Its remit is to advise the Trustees about the Society’s pay policy. It meets annually to agree the remuneration of the staff employed by the Society, by considering the recommendations of the Society’s Chief Executive following annual performance development reviews and considers the remuneration of the Chief Executive. The Committee also reviews the BTS Staff Handbook and annual amendments and updates. With the approval of the Board, the Committee has been renamed as the People and Culture Committee.

Annual appraisals were conducted in May 2025. The outcome of appraisals informs the recommendations to the Remuneration Committee about pay awards and annual progression of individuals. The Committee met in June 2025, and agreed an inflation-linked pay increase of 3.5% for the 2025/26 year.

Risk Assessment and Management

The Society’s Senior Management Team review the Risk Assessment matrix every quarter, taking actions to mitigate or remove risk as appropriate and where possible, and prepare an update for the Board’s review in June each year. Risks are assessed in terms of the key areas of the organisation: Membership, Finance, Building, Business continuity, People, Planning and review, IT and Information Governance, Strategy and Review. Each component of the register is given an overall score which reflects the likelihood of the risk occurring times the impact. The most significant risk is that of a reduction of income from the journal Thorax given the changing nature of publication models. This has been kept under close review for several years and currently the funding stream has held up well. The annual risk review and management plan was undertaken in the final quarter of the year, focussing again on operational and financial recovery matters, and the report was approved by the Board in June 2025.

19

BTS Annual Report 2024/25

The Senior Management Team monitors the possible impact on income and expenditure of the range of BTS activities. Trustees stand ready to act on advice received and to take steps to maintain the future health of the Society.

Fundraising

Practice

The Society does not engage in public fundraising and does not use professional fundraisers or commercial participants. It has not received any complaints relating to fundraising practice.

Related Party Transactions

There were no related party transactions during the 2024/25 year (2023/24: none). Trustees have added into the Standing Instructions for conduct of business the need to treat any further transactions with related parties as an Item of Reserved Business. This means that in future, the Officers’ Group will consider any further situations that might arise and will make a recommendation to the full Board if they wish to enter into any similar arrangement(s). The Board will be required to give final approval, or otherwise.

Relationship with Biomedical Industries

Since 1999, the Society has had a policy to support its relationship with the biomedical industry, and in all subsequent years has sought related Declarations of Interest from all members who have undertaken work on its behalf. Since June 2013, the Declarations of Interest have been published on the open-access area of its website. These come from all who are involved in BTS Committees, Guidelines groups, SAGs and ad-hoc Working Parties. During the year, Trustees and Council reviewed and amended this policy, and confirmed the Society’s policy on endorsement, which states that, wherever possible, support from a single commercial source for BTS activities should not be sought or accepted. In general, the Society does not endorse any activity – including that which originates from non-commercial organisations - unless it has been involved as a partner from the start. Appendix B gives details of all companies from which the Society received support during the year.

20

BTS Annual Report 2024/25

STATEMENT OF RESPONSIBILITIES OF TRUSTEES

Members of the Board of Trustees (who are also directors of The British Thoracic Society for the purposes of company law) are responsible for preparing the Board’s report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Board to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Board is required to:

Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation

The Board is responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). The Board is also responsible for safeguarding the assets of the charitable and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as Board members are aware:

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The total number of such guarantees at 30 June 2024 was 4,687 (2023: 4,480). Each of the Board members is a member of the charity, but this entitles them only to voting rights. No members of the Board have any beneficial interest in the charity.

The report of the Board has been prepared in accordance with the special provisions applicable to companies subject to the small companies’ regime.

Approved by the Board of Trustees on 2 October 2025 and signed on its behalf by: Richard Russell

Dr Richard Russell

21

BTS Annual Report 2024/25

Company number 1645201 - Incorporated in the United Kingdom

Charity numbers

285174 – Registered in England and Wales

SC041209 – Registered in Scotland

Registered office 17 Doughty Street

and operational London address WC1N 2PL

Trustees Trustees, who are also Directors under company law, who served during the year and up to the date of this report were as follows:

Trustees Roles
Dr Martin Allen MBE Trustee - Gettingit Right First Time Lead
Mrs Alison Armstrong Chair,Education and TrainingCommittee
Professor Mona Bafadhel Chair, Science & Research Committee
From November 2024
Professor Jonathan Bennett President to November 2024
Professor James Chalmers Chair, Science & Research Committee
to November 2024
Professor Robina Coker President-Elect from November 2024
Ms Lucy Davies LayTrustee from November 2024
Professor Andres Floto HonorarySecretary
Dr Alanna Hare HonoraryTreasurer
Professor Adam Hill Chair,Standards of Care Committee
Dr Mark Juniper Chair, Quality Improvement Committee to
November 2024
Professor Nick Maskell President-elect to November 2024
President from November 2024
Dr Andrew Molyneux Chair, Quality Improvement Committee from
November 2024
Ms Caroline Nokes LayTrustee from November 2024
Dr Richard Russell Chair of the Board from November 2024
Dr Daniel Smith Chair, Workforce and Service Development
Committee
Dr Laura-Jane Smith Trustee,Environment and Sustainability
Dr Paul Walker Chair of the Board to November 2024

22

BTS Annual Report 2024/25

Staf Post
Angela Barnes MembershipManager
Billie Barron-West Communications Coordinator, from November
2024
Deborah Broughton Executive Assistant
**Bernice Bruce-Vanderpuije ** Co-ordinator,Clinical and Strategic Programmes
Amanda Crispin Finance Manager,from September 2024
Suzanne Howard Coordinator,MDRTB Clinical Advice Service
Shani Kennedy Head of Operations – maternity cover March to
September 2024
Rajeev Lahkar CRM Manager
Maria Loughenbury Manager,LungDiseases Registry
Kate McNaboe Conference Manager,from September 2024
Christina Moll Manager,Improvement and Standards
Rosie O’Carroll Head of Strategic Communications
Kirstie Opstad Manager,Guidelines andQualityStandards
Louise Preston Head of Strategic Programmes
Ranjit Nandra IT and Systems Support
Alexandra Saywell Communications Specialist,to November 2024
Miguel Souto Head of Clinical Programmes
Joan Thompson Head of Finance,to September 2024
Trine Tofte Coordinator, Education and Events, to November
2024
Ted Upton-Newall Administrator, Education and Events from
February2025
Sally Welham Chief Executive
Kathryn Wilson Head of Operations

Bankers Co-operative Bank, 60 Kingsway, London WC2B 6DS Solicitors BDB Pitmans LLP, 50/60 Station Road, Cambridge CB1 2JH - from April 2024 Investment Evelyn Partners (formerly Tilney Asset Management Limited) Managers 6 Chesterfield Gardens, London W1J 5BQ Accountants JS2 Limited

One Crown Square, Church Street East, Woking, Surrey GU21 6HR

Auditor HaysMac LLP, 10 Queen Street Place, London EC4R 1AG

23

BTS Annual Report 2024/25

Independent auditor’s report to the members and trustees of The British Thoracic Society

Opinion

We have audited the financial statements of The British Thoracic Society (“the charitable company”) for the year ended 30 June 2025 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows, and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

24

BTS Annual Report 2024/25

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report (which incorporates the strategic report and the directors’ report).

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charity Accounts (Scotland) Regulations (as amended) requires us to report to you if, in our opinion:

Responsibilities of trustees for the financial statements

As explained more fully in the trustees’ responsibilities statement [ set out on page 21] the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the charitable company and the environment in which it operates, we identified that the principal risks of non-compliance with laws and regulations related to the Companies Act 2006, Charities Act 2011, Charity Accounts (Scotland) Regulations (as amended), and Charities and Trustee Investment (Scotland) Act 2005, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as payroll tax and sales tax.

We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate journal entries to revenue and management bias in accounting estimates. Audit procedures performed by the engagement team included:

25

BTS Annual Report 2024/25

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Thomas Wilson (Senior Statutory Auditor) 10 Queen Street Place For and on behalf of HaysMac LLP, Statutory Auditor London EC4R 1AG Date: 07/10/2025

26

The British Thoracic Society

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 30 June 2025

Income from:
Note
Charitable activities
Membership
2
Donations
2
Standards and Education
2
Research and Innovation
2
Investments
3
Total income
Expenditure on:
Investment Management costs
4
Charitable activities
Membership
4
Standards and Education
4
Research and Innovation
4
Profile
4
Total expenditure
Net (expenditure)/income before net gains
on investments
Net (losses)/gains on investments
Net (expenditure)/income for the year
5
Transfers between funds
Net (expenditure)/income and net
movement in funds
Net (expenditure)/income for the year and
net movement in funds
Reconciliation of funds:
Total funds brought forward
17
Total funds carried forward
17		 Unrestricted
Restricted
2025
Total
£
£
£
747,363
-
747,363
-
-
-
474,144
59,243
533,387
1,789,236
-
1,789,236
95,691
-
95,691
3,106,434
59,243
3,165,677
44,204
-
44,204
158,713
-
158,713
1,169,859
235,505
1,405,364
1,274,666
-
1,274,666
442,746
-
442,746
3,090,188
235,505
3,325,693
16,246
(176,262)
(160,016)
(109,519)
-
(109,519)
(93,273)
(176,262)
(269,535)
(89,651)
89,651
-
(182,924)
(86,611)
(269,535)
(182,924)
(86,611)
(269,535)
7,379,137
106,611
7,485,748
7,196,213
20,000
7,216,213		 Unrestricted
Restricted
2024
Total
£
£
£
715,842
-
715,842
2,658
-
2,658
487,011
159,306
646,317
1,639,611
-
1,639,611
74,689
-
74,689
2,919,811
159,306
3,079,117
43,167
-
43,167
-
150,971
-
150,971
1,216,042
136,226
1,352,268
1,111,146
-
1,111,146
394,688
29,779
424,467
2,916,014
166,005
3,082,019
3,797
(6,699)
(2,902)
341,724
-
341,724
345,521
(6,699)
338,822
(82,940)
82,940
-
262,581
76,241
338,822
262,581
76,241
338,822
7,116,556
30,370
7,146,926
7,379,137
106,611
7,485,748

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 17 to the financial statements.

27

The British Thoracic Society

Company no. 1645201

Balance sheet

As at 30 June 2025

Note
Fixed assets:
Tangible assets
11
Investments
12
Current assets:
Debtors
13
Cash at bank and in hand
Liabilities:
Creditors: amounts falling due within one year
14
Net current assets
Total net assets
The funds of the charity:
Restricted income funds
17
Unrestricted income funds:
Designated funds
General funds
Total unrestricted funds
Total charity funds		 £
877,723
1,867,191		 2025
£
1,514,343
4,689,317		 £
649,276
1,894,738		 2024
£
1,468,873
4,692,440
6,203,660
1,012,553		 6,161,313
1,124,435
2,744,914
(1,732,361)		 2,544,014
(1,419,579)
6,321,582
874,631		 6,497,925
881,212
7,216,213 7,285,748
20,000
7,196,213		 106,611
7,379,137
7,216,213 7,485,748

The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

Approved by the Board of Trustees on 2nd October 2025 and signed on its behalf by

Alanna Hare

Dr. Alanna Hare Honorary Treasurer

28

The British Thoracic Society

Statement of cash flows

For the year ended 30 June 2025

Cash flows from operating activities
Note
18
Net cash used in operating activities
Cash flows from investing activities:
Dividends, interest and rents from investments
Purchase of fixed assets
Proceeds from investments
Purchase of investments
Movement in cash held by investment managers
Net cash provided by investing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
2025
£
£
(122,611)
95,691
(94,231)
678,330
(536,814)
(47,912)
95,064
(27,547)
1,894,738
1,867,191		 2024
£
£
(15,080)
74,689
(2,113)
846,745
(741,534)
6,746
184,533
169,453
1,725,285
1,894,738
(27,547)
1,894,738		 169,453
1,725,285
1,867,191 1,894,738

29

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

1 Accounting policies

a) Statutory Information

The British Thoracic Society is a charitable company limited by guarantee and is incorporated in England and Wales (company registration number 01645201). The registered office address is 17 Doughty Street, London, WC1N 2PL.

b) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (September 2015) and the Companies Act 2006.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

c) Public benefit entity

The charitable company meets the definition of a public benefit entity under FRS 102.

d) Going concern

The Trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern and accordingly have prepared the accounts on a going concern basis.

e) Principal risks and uncertainties

The Trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

f) Income

The key income streams are from Journals, Meetings and Membership.

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably. Membership income is accounted for in the period to which it relates. Membership reciepts in advance are recorded as deferred income.

Income from government and other grants, whether ‘capital’ grants or ‘revenue’ grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met.

Investment Income & Interest receivable

Investment income and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

g) Fund accounting

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Unrestricted funds are donations and other income received or generated for the charitable purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

30

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

1 Accounting policies (continued)

h) Expenditure (including grants) and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

Raising funds (investment manager fees)

Expenditure on charitable activities includes the costs of delivering services, Meetings and other educational activities undertaken to further the purposes of the charity and their associated support costs

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

i) Allocation of support costs

Expenditure is allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function, is apportioned on the following basis which are an estimate, based on staff time, of the amount attributable to each activity.

Standards and Education 38%
Research 9%
Profile 16%
Membership 6%
Support costs 19%
Governance costs 11%

Support and governance costs are re-allocated to each of the activities on the following basis which is an estimate, based on staff time, of the amount attributable to each activity

Standards and Education 55%
Research 13%
Profile 23%
Membership 9%

Governance costs, included within total support costs, are the costs associated with the governance arrangements of the charity, namely the costs of constitutional and statutory requirements and include any costs associated with the strategic management of the charity’s activities.

j) Operating leases

Rental charges are charged on a straight line basis over the term of the lease.

31

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

1 Accounting policies (continued)

k) Tangible fixed assets

Items of equipment are capitalised where the purchase price exceeds £500. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

Where fixed assets have been revalued, any excess between the revalued amount and the historic cost of the asset will be shown as a revaluation reserve in the balance sheet.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures & Fittings 10 years
Computer Equipment & Website 3 years
CRM Software 10 years
Freehold buildings 50 years
Land Not Depreciated

l) Listed investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. Any change in fair value will be recognised in the statement of financial activities and any excess of fair value over the historic cost of the investments will be shown as a fair value reserve in the balance sheet. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading “Net gains/(losses) on investments” in the statement of financial activities. The charity does not acquire put options, derivatives or other complex financial instruments.

m) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

n) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

o) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

32

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

1 Accounting policies (continued)

BTS established an auto-enrolment defined contribution scheme with Legal & General with effect from 1 January 2016 (12 months earlier than required by statute) and makes employer contributions into this scheme. For employees who had their own schemes in place before this date BTS continues to make contributions into their individual schemes. Employer contributions are the same for all employees, on a sliding scale depending on employee contributions as specified in contracts of employment, and those in the auto-enrolment scheme increased their contributions during the year in line with statutory minima.

33

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

2 Income from charitable activities

Donations
Me
Sta
Res
Total income from charitable activities
Donations
Sub-total for Donations
mbership
Membership
Sub-total for Membership
ndards and Education
Short courses
Summer Meeting
Speciality Certificate Examination
MDRTB project
Committees
Conference awards
British Sleep Society
Sub-total for Education and Standards
earch and Innovation
Thorax
Research Training Day
Winter Meeting
Sub-total for Research and Innovation		 Unrestricted
£
-
-
747,363		 Restricted
£
-
-
-		 2025
Total
£
-
-
747,363		 2024
Total
£
2,658
2,658
715,842
747,363
228,959
239,185
-
-
6,000
-
-		 -
-
-
-
44,000
-
15,243
-		 747,363
228,959
239,185
-
44,000
6,000
15,243
-		 715,842
247,665
217,798
21,548
44,000
-
5,306
110,000
474,144
588,448
50
1,200,738		 59,243
-
-
-		 533,387
588,448
50
1,200,738		 646,317
631,755
-
1,007,856
1,789,236 - 1,789,236 1,639,611
3,010,743 59,243 3,069,986 3,004,428

34

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

2
Income from charitable activities (continued)
Prior Year
Donations
Donations
Sub-total for Donations
Membership
Membership
Sub-total for Membership
Standards and Education
Short courses
Summer Meeting
Speciality Certificate Examination
MDRTB project
Tobacco Dependency Programme
Committees
Conference Awards
British Sleep Society
Sub-total for Education and Standards
Research and Innovation
Thorax
Winter Meeting
Sub-total for Research and Innovation
Total income from charitable activities		 Unrestricted
£
2,658
2,658
715,842
715,842
247,665
217,798
21,548
-
-
-
-
-
487,011
631,755
1,007,856
1,639,611
2,845,122		 Restricted
£
-
-
-
-
-
-
-
44,000
-
-
5,306
110,000
159,306
-
-
-
159,306		 2024
Total
£
2,658
2,658
715,842
715,842
247,665
217,798
21,548
44,000
-
-
5,306
110,000
646,317
631,755
1,007,856
1,639,611
3,004,428

3 Income from investments

Income from investments
Income from listed investments Unrestricted
£
95,691
95,691		 2025
Total
£
95,691		 2024
Total
£
74,689
95,691 74,689

In the year to 30 June 2025, all income from listed investments was unrestricted.

35

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

4 Analysis of expenditure

Staff costs (Note 6)
Conferences
Committees & guidelines
Courses
Publications
Public relations
Project & consortia costs
Investment management
Other
Support costs
Property
IT costs
Office running costs
Depreciation
Audit
Accountancy
Council, AGM & Board
Irrecoverable VAT
Other
Support Costs
Governance Costs
Total expenditure 2025
Total expenditure 2024		 Investment
Management
Costs
£
-
-
-
-
-
-
-
44,204
-		 Charitable activities Charitable activities Profile
£
193,979
-
-
-
-
27,632
-
-
-		 Governance
£
139,070
-
-
-
-
-
-
-
-		 Support
£
2025 Total
£
234,188
1,215,297
-
936,093
-
42,235
1,454
133,967
-
351,990
3,709
31,341
-
1,523
-
44,204
-
-		 2024 Total
£
1,111,228
851,152
37,241
136,664
308,203
29,483
498
43,167
44
Membership
£
74,046
-
-
-
-
-
-
-
-		 Standards &
Education
£
459,461
231,734
42,235
132,513
13,427
-
1,523
-
-		 Research
£
114,553
704,359
-
-
338,563
-
-
-
-
44,204
-
-
-
-
-
-
-
-
-
-
-
44,204		 74,046
-
-
-
-
-
-
-
-
-		 880,893
-
7,816
-
-
-
-
-
-
-		 1,157,475
-
-
-
-
-
-
-
-
-		 221,611
-
4,080
-
-
-
-
-
-
-		 139,070
-
-
-
-
21,150
-
323
-
-		 239,351
2,756,650
62,912
62,912
65,595
77,491
138,972
138,972
48,761
48,761
-
21,150
23,612
23,612
-
323
165,894
165,894
29,928
29,928		 2,517,680
80,785
99,316
97,460
50,907
19,950
22,691
-
165,260
27,970
70,138
14,529
158,713		 427,998
88,657
1,405,364		 97,081
20,110
1,274,666		 179,808
37,247
442,746		 -
(160,543)
-		 (775,025)
-
-
-
3,325,693
43,167 150,971 1,352,268 1,111,146 424,467 - - 3,082,019

Of the total expenditure, £3,090,188 was unrestricted (2024: £2,916,014) and £235,504 was restricted (2024: £166,005).

36

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

4 Analysis of expenditure - Prior Year

Staff costs (Note 6)
Conferences
Committees & guidelines
Courses
Publications
Public relations
Project & consortia costs
Investment management
Other
Support costs
Property
IT costs
Office running costs
Depreciation
Audit
Accountancy
Council, AGM & Board
Irrecoverable VAT
Other
Support Costs
Governance Costs
Total expenditure 2024
Total expenditure 2023		 Investment
Management
Costs
£
-
-
-
-
-
-
-
43,167
-		 Charitable activities Charitable activities Profile
£
168,891
-
-
-
-
29,448
-
-
-		 Governance
£
156,087
-
-
-
-
-
-
-
-		 Support
£
2025 Total
£
227,174
1,111,228
-
851,152
-
37,241
229
136,664
-
308,203
35
29,483
-
498
-
43,167
-
44		 2024 Total
£
964,851
683,723
16,700
124,204
299,952
58,039
249
40,851
-
Membership
£
65,880
-
-
-
-
-
-
-
44		 Standards &
Education
£
402,010
257,112
37,241
136,435
-
-
498
-
-		 Research
£
91,186
594,040
-
-
308,203
-
-
-
-
43,167
-
-
-
-
-
-
-
-
-
-
-
43,167		 65,924
-
-
-
-
-
-
-
-
-		 833,296
-
-
-
-
-
-
-
-
-		 993,429
-
-
-
-
-
-
-
-
-		 198,339
-
8,100
-
-
-
-
-
-
-		 156,087
-
-
-
-
19,950
-
-
-
-		 227,438
2,517,680
80,785
80,785
91,216
99,316
97,460
97,460
50,907
50,907
-
19,950
22,691
22,691
-
-
165,260
165,260
27,970
27,970		 2,188,569
73,409
88,764
102,642
48,000
17,670
20,413
15,000
109,506
28,926
69,116
15,931
150,971		 421,758
97,214
1,352,268		 95,666
22,051
1,111,146		 177,187
40,841
424,467		 -
(176,037)
-		 (763,727)
-
-
-
3,082,019
40,851 136,405 1,140,719 998,592 376,332 - - 2,692,899

37

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

5 Net income / (expenditure) for the year

This is stated after charging / (crediting):

This is stated after charging / (crediting):
2025 2024
£ £
Depreciation 48,761 50,906
Operating lease rentals:
Equipment
Auditors' remuneration (excluding VAT):
Audit 21,150 19,950

6 Analysis of staff costs, Trustee remuneration and expenses, and the cost of key management personnel

Staff costs were as follows:

Salaries and wages
Social security costs
Employer’s contribution to defined contribution pension schemes
Recruitment
Other forms of employee benefits
Staff Development & HR		 2025
2024
£
£
948,878
889,433
101,608
96,323
122,602
111,760
29,468
5,325
822
494
11,919
7,893
1,215,297
1,111,228

The following number of employees received employee benefits (excluding employer national insurance and employer pension costs) during the year between:

costs) during the year between:
2025 2024
No. No.
£60,000 - £69,999 2 3
£70,000 - £79,999 2 1
£80,000 - £89,999 - -
£90,000 - £99,999 1 -
£100,000 - £109,999 - 1

The total employee benefits including employer's national insurance and pension contributions of the key management personnel were £454,411(2024: £461,393).

No termination payments were made during the year (2024: £nil).

The charity Trustees were not paid or received any other benefits from employment with the charity in the year (2024: £nil). No charity trustee received payment for professional or other services supplied to the charity (2024: £nil).

Trustees' expenses represents the payment or reimbursement of travel and subsistence costs totalling £13,964 (2024: £12,035) incurred by 14 (2024: 10) members relating to attendance at meetings of the Trustees.

38

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

7 Staff numbers

The average number of employees (head count based on number of staff employed) during the year was as follows:

Membership
Standards & Education
Research & Innovation
Profile
Governance
Support		 2025
No.
2024
No.
1.1
1.1
6.9
6.4
1.6
1.5
2.9
2.7
2.1
2.5
3.5
3.6
18.1
17.8

8. Grants Awarded

2025
Attendees
Best Practice Fellowship
BTS Winter Meeting
29
29
29
2025
2024
2024
£
Attendees
£
25,375
34
29,625
25,375
34
29,625
25,375
34
29,625

Best Practice Fellowship

29 grants were made in September 2024 for the 2024 Winter Meeting.

9 Related party transactions

There were no related party transactions this year, or donations from related parties.

10 Taxation

The charitable company is exempt from corporation tax as all of its income is charitable and is applied for charitable purposes.

39

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

11 Tangible fixed assets

Cost or valuation
At the start of the year
Additions in year
Disposals in year
At the end of the year
Depreciation
At the start of the year
Charge for the year
Eliminated on disposal
At the end of the year
Net book value
At the end of the year
At the start of the year		 Freehold
property
£
Fixtures and
fittings
£
Computer
equipment
£
Total
£
1,935,316
94,865
336,688
2,366,869
75,424
1,585
17,222
94,231
-
-
(4,113)
(4,113)
2,010,740
96,450
349,797
2,456,987
509,185
87,093
301,718
897,996
31,309
5,786
11,666
48,761
-
-
(4,113)
(4,113)
540,494
92,879
309,271
942,644
1,470,246
3,571
40,526
1,514,343
1,426,131
7,772
34,970
1,468,873

Land with a value of £390,000 (2024: £390,000) is included within freehold property and not depreciated.

All of the above assets are used for charitable purposes.

12 Listed investments

Listed investments
Fair value at the start of the year
Additions at cost
Disposal proceeds
Net gain on change in fair value
Cash held by investment broker pending reinvestment
Fair value at the end of the year
Historic cost at the end of the year
Investments comprise:
UK quoted investments
Overseas quoted investments
Cash		 2025
2024
£
£
4,887,288
4,650,775
536,814
741,534
(678,330)
(846,745)
(109,519)
341,724
4,636,253
4,887,288
53,064
5,152
4,689,317
4,892,440
3,195,544
3,219,809
2025
2024
£
£
1,731,976
1,747,219
2,904,277
3,140,069
53,064
5,152
4,689,317
4,892,440

40

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

13 Debtors

Trade debtors
Prepayments
Accrued income
Prepayments includes deposits for future Winter Meetings as follows:
Due in 1-2 years
Due in 2-5 years
Creditors: amounts falling due within one year
Trade creditors
Other creditors
Accruals
Deferred income (Note 15)
Taxes and Social Security		 2025
£
2024
£
309,757
112,295
286,110
265,135
281,856
271,846
877,723
649,276
2025
2024
£
£
107,925
75,476
87,700
105,797
195,625
181,273
2025
£
2024
£
75,874
36,750
178,725
166,738
204,318
210,951
1,228,261
951,063
45,183
54,077
1,732,361
1,419,579

14 Creditors: amounts falling due within one year

15 Deferred income

Deferred income comprises of membership subscriptions received during the period 1 July 2024 to 30 June 2025 relating to 1 July 2025 to 30 June 2026, and income received for short courses in advance of the course taking place.

Balance at the beginning of the year
Amount released to income in the year
Short Courses
Membership
Winter Meeting - Exhibitor income
Winter Meeting - Delegate income
Balance at the end of the year		 2025
£
2024
£
951,063
783,175
(951,063)
(783,175)
101,573
65,183
709,478
686,545
409,010
189,200
8,200
10,135
1,228,261
951,063

41

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

16 Analysis of net assets between funds 2025

Analysis of net assets between funds 2025
Tangible fixed assets
Investments
Current assets
Current liabilities
Net assets at the end of the year
Analysis of net assets between funds 2024
Tangible fixed assets
Investments
Current assets
Current liabilities
Net assets at the end of the year		 General
Designated
unrestricted
Funds
Restricted
Total funds 2025
£
£
£
£
-
1,514,343
-
1,514,343
-
4,689,317
-
4,689,317
2,606,992
117,922
20,000
2,744,914
(1,732,361)
-
-
(1,732,361)
874,631
6,321,582
20,000
7,216,213
General
Designated
unrestricted
Funds
Restricted
Total funds 2024
£
£
£
£
-
1,468,873
-
1,468,873
-
4,892,440
-
4,892,440
2,300,791
136,612
106,611
2,544,014
(1,419,579)
-
-
(1,419,579)
881,212
6,497,925
106,611
7,485,748

17 Movements in funds 2025

Movements in funds 2025
Restricted funds:
Tobacco Dependency Programme
Travel Grants
Irish Thoracic Society
British Sleep Society
TB
Total restricted funds
Unrestricted funds:
Designated funds:
Property Fund
Property Maintenance Fund
Investment Fund
Fixed Assets Fund
Legacy
Total designated funds
General funds
Total unrestricted funds
Total funds		 At the start
Income &
Expenditure
At the end of the
of the year
£
Gains
£
& losses
£
Transfers
£
year
£
-
-
-
-
-
6,051
15,243
(14,500)
13,206
20,000
-
-
(1,670)
1,670
-
100,560
-
(100,496)
(64)
-
-
44,000
(118,839)
74,839
-
106,611
59,243
(235,505)
89,651
20,000
1,426,131
-
(31,309)
75,424
1,470,246
8,687
-
(14,032)
5,345
-
4,892,440
(38,919)
(44,204)
(120,000)
4,689,317
42,745
-
(17,452)
18,804
44,097
127,922
-
-
(10,000)
117,922
6,497,925
(38,919)
(106,997)
(30,427)
6,321,582
881,212
3,035,834
(2,983,191)
(59,224)
874,631
7,379,137
2,996,915
(3,090,188)
(89,651)
7,196,213
7,485,748
3,056,158
(3,325,693)
-
7,216,213

42

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

17 Movements in funds 2024

Restricted funds:
Tobacco Dependency Programme
Travel Grants
British Sleep Society
TB
Total restricted funds
Unrestricted funds:
Designated funds:
Property Fund
Property Maintenance Fund
Investment Fund
Fixed Assets Fund
Legacy Fund
Total designated funds
General funds
Total unrestricted funds
Total funds		 At the start
of the year
£
Income &
Gains
£
Expenditure
& losses
£
Transfers
£
At the end of the
year
£
-
-
(29,779)
29,779
-
30,370
5,306
(29,625)
-
6,051
110,000
(9,440)
100,560
44,000
(97,161)
53,161
-
30,370
159,306
(166,005)
82,940
106,611
1,457,037
-
(30,906)
-
1,426,131
28,339
-
(19,652)
-
8,687
4,662,672
399,944
(43,167)
(127,009)
4,892,440
60,634
-
(20,002)
2,113
42,745
125,264
2,658
-
-
127,922
6,333,946
402,602
(113,727)
(124,896)
6,497,925
782,610
2,858,933
(2,802,287)
41,956
881,212
7,116,556
3,261,535
(2,916,014)
(82,940)
7,379,137
7,146,926
3,420,841
(3,082,019)
-
7,485,748

43

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

Purposes of restricted funds

Conference Awards

Financial support for this scheme, formerly Travel Grants, came originally from GSK and Vertex in 2017/18. In 2024/25, £5,000 was received from GSK and £5,000 from Astra Zeneca. BTS contributed an additional £10,000 from within its own funds. The grants are offered in open competition to all respiratory healthcare professionals, and are intended to support the costs of attending respiratory conferences in the UK. The applicants are asked to demonstrate how their abstracts submitted for these conferences will help improve patient care. The awards are allocated on the basis of anonymous scoring. In this financial year, 29 grants were made to support attendances and awards at the Winter Meeting 2024. The funders have no input into the criteria for the grants, or the selection of the recipients.

British Sleep Society

BTS was awarded a sub-contract from the British Sleep Society in relation to funds awarded from Health Education England for the support of education in physiological sciences for those working in respiratory medicine and health care. The funds award in the previous year have been fully spent on educational resources including 2 series of specially commissioned webinars.

TB – MDRTB Clinical Advice Service

BTS facilitates the Multi-Drug Resistant Tuberculosis Clinical Advice Service which allow clinicians across the four nations to seek advice on complex MDR-TB cases. NHS England has supported this activity with a small grant on an annual basis for a number of years. BTS supplements the full cost of the activity from within its own resources.

Irish Thoracic Society

BTS agreed to work with the Irish Thoracic Society to offer a joint meeting in Belfast with the Ulster Thoracic Society. The BTS/ITS/UTS joint meeting took place in March 2025. The ITS undertook the majority of the organisation and administration, with BTS providing staff to support the meeting on the day, and travel expenses for a number of BTS Officers. The purpose of the meeting was to provide a day of continuing professional development for respiratory health care professionals in both northern and southern Ireland.

Purposes of designated funds

Property Fund

The freehold of 17 Doughty Street was purchased in 2001. The fund balance represents the book value of the property including refurbishment costs. The building was valued in July 2017 - £2,800,000.

Property Maintenance Fund

The Society designates funds in order to maintain the building and meet contingencies, and has a five-year property maintenance schedule.

Investment Fund

In accordance with the reserves policy outlined in the Trustees Report, this Fund represents the value of the investment portfolio less amounts accrued and committed for refurbishments.

Fixed Asset Fund

The fixed assets fund is equivalent to the net book value of the fixtures and fittings and computer equipment. This fund has been set aside to cover the future depreciation of these fixed assets.

Legacy Fund

BTS received one legacy in 2022/23 and a further legacy was received in 2023/24, totalling £127,922. In 2024/25, Trustees have agreed to allocate a sum from these funds to supplement the conference award scheme to facilitate attendance at the Winter Meeting 2024.

44

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2025

18 Reconciliation of net income / (expenditure) to net cash flow from operating activities

Net (expenditure) / income for the reporting period
(as per the statement of financial activities)
Depreciation charges
Loss/(Gains) on investments
Dividends, interest and rent from investments
(Increase) in debtors
Increase in creditors
Net cash provided by operating activities		 2025
2024
£
£
(269,535)
338,822
48,761
50,906
109,519
(341,724)
(95,691)
(74,689)
(228,447)
(146,292)
312,782
157,897
(122,611)
(15,080)

19 Legal Status

The charity is a company limited by quarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

20 Capital commitments

At 30 June 2025 the charity had capital commitments of £369,612 (2024 -£nil).

45

Appendix A

A

Andrew Achaiah Dinesh Addala Charlotte Addy Sanjay Agrawal Rizwan Ahmed Ahsan Akram Anna Alderslade Eliza Alexander Martin Allen Lynn Altass Joseph Aluoch Sundari Ampikaipakan Sachin Ananth Sarah Anderson Joseph Annandale Pearlene Antoine-Pitterson Alison Armstrong Darius Armstrong-James Parniya Arooj Stephen Aston Avinash Aujayeb Ezabella Ayele Jonathan Ayling-Smith Aqeem Azam

B

Matthijs Backx

Huda Badri Mona Bafadhel Lucy Baker Haval Balata Christopher Barber Shaney Barratt Simon Barry Stephen Barry Emily Bartlett Sam Bartlett-Pestell Caroline Baxter Eihab Bedawi Amsalu Bekele Binegdie David Bell Rachel Benamore Amy Bendall Jonathan Bennett Andrew Bentley Malin Bergstrom Malvika Bhatnagar Jayesh Mahendra Bhatt Anna Bibby Surinder Birring Chloё Bloom Graham Bloye Charlotte Bolton Beverley Bostock Graham Bothamley Stephen Bourke Aaron Braddy-Green

Kate Bradfield Daniel Braga Darryl Braganza Menezes Malcolm Brodlie Catherine Brown James Brown Jeremy Brown Michael Brown Janette Browne Clare Burton Andrew Bush Jennifer Butler Maria Buxton

C

Matthew Callister Jack Callum Liam Campbell Santino Capocci Toby Capstick Ellis Cerrone Sarah Chamberlain Mitchell Cathleen Chan Emma Chaplin Nazia Chaudhuri Aneeka Chavda Christabelle Chen Felix Chua Colin Church Richard Coker Robina Coker

Meg Coleman Suzi Coles Hannah Collins David Connell John Corcoran Sharon Cox Andrew Creamer Anita Critchlow Ian Cropley Andrew Cumpstey

D

Rebecca D’Cruz Rachel Daly Gráinne d'Ancona Janet Darbyshire Alice Davies Gerry Davies Lucy Davies Michael Davies Peter Davies Sally Davies Dhiren Dayal Enya Daynes Martin Dedicoat Patrick Dennison Poppy Denniston Anthony de-Soyza Anand Devaraj Devesh Dhasmana Sarah Diver

Giles Dixon Sarah Doffman Damian Downey Francis Drobniewski Ingrid Du Rand James Duckers Hamish Duff Akshay Dwarakanath

E

Carlos Echevarria Christopher Edwards Sarah Elkin Huw Ellis Omer Elneima Lynn Elsey Alguili Elsheikh Odiri Eneje Rachael Evans Matthew Evison

F

Johanna Feary Jeff Featherstone Timothy Felton Mariana Fernandes Laura Ferreras-Antolin Debbie Field Lydia Finney David Fishwick

Tracey Fleming Sophie Fletcher Katia Florman Andres Floto William Flowers Cara Flynn Verity Ford Miriam Formica Richard Foster Jonathan Fuld Elizabeth Fuller Duncan Fullerton Wendy Funston

G

Aleksandra Gawlik-Lipinski Francis Gilchrist Thomas Gorsuch Louis Grandjean Nikki Gray Neil Greening Jack Grenville Lizzie Grillo Ashley Groves Frances Grudzinska Kevin Gruffydd-Jones

H

Guy Hagan Jemma Haines

Pranabashis Haldar Rachel Halliday Rob Hallifax Alex Haragan Alanna Hare Mohammed Haris James Harper Natalie Harper Samantha Harrison Stephen Harrow Ricky Harwood Sara Hayes Dominic Heining Christine Henderson Hazel Henderson Sarah Hennessey Richard Hewitt Izak Heys Adam Hill Natalie Hill Stephen Hindle Sabrine Hippolyte Barnaby Hirons David Ho Sharon Hodge Clare Hodkinson Jorg Hoffman Paul Holland Steve Holmes Clare Hooper Carolyn Horst Imran Howell

Ola Howell Patrick Howlett Jennifer Hoyle Gareth Hughes James Hull George Hulston Graeme Hunter Christopher Huntley John Hurst Katharine Hurt

I

Wadah Ibrahim John Innes Beenish Iqbal Sriram Iyer

J

David Jackson Susan Jackson Shamanthi Jayasooriya Bronwen Jenkinson Jillian Johnston Ben Jones Ricardo Jose Mark Juniper

K

Tamanna Kabir

Hanna Kaur Tabitha Kavoi Jennie Keane Sarah Kearney Fasihul Khan Haji M Sheeraz Khan Onn Min Kon Samantha Kon Ayesha Kumar Kartik Kumar Rashmi Kumar Heinke Kunst

L

Kirsty Laing Tracey Langham Ian Laurenson Andy Lee Julian Legg Cara Lewis Dana Li Konstantinos Liatsikos Patrick Lillie Wei Shen Lim Marc Lipman Kate Lippiett Eric Livingston Vikki Lloyd David Lo Ahmad Lodhi Michael Loebinger

Tuck-Kay Loke Siobhan Ludlow Fiona Lynch

M

Jim Macfarlane Alison Mackenzie Adele Mackin Abigail Mackintosh Thomas MacMahon Yvonne Macnicol Lavinia Magee Anirban Maitra William Man Kavina Manalan Swapna Mandal Rachel Manners Stephanie Mansell Ari Manuel Daniella Marks Paul Marsden Henry Marshall Matthew Martin Anthony Martinelli Jennifer Martinovic Refiloe Masekela Izhaq Masih Nicholas Maskell Arshiya Mastan Paul Mccallion Andrew Mccallum

Duncan McCormick Louise McCorry David Mccracken Helen McDill Jane Mcdowell Lorcan McGarvey Fiona McGill Paul McKeagney Sarah McLeod Jim McMenamin Laura McNaughton Thomas Medveczky Jamilah Meghji Ellen Mekonnen Sarah Menzies Ben Messer Fraser Millar James Millard Gemma Miller Stephen Milward Paul Minnis Victoria Molyneaux Andrew Molyneux Olga Moncayo David Moore Vicky Moore John Moore-Gillon Rachel Moores Alyn Morice Helen Morris Fiona Mosgrove Andrew Mountain

Sarah Mulholland Anna Murphy Patrick Murphy Ye Myat

N

Prasad Nagakumar Sindhu Naidu Arjun Nair Marium Naqvi Manjith Narayanan Sushiladevi Natarajan Neal Navani Joseph Newman Jennifer Nixon Caroline Nokes Claire Nolan

O

Emma O'Dowd Ronan O'Driscoll James O'Hara Sandra Olive Femi Oshin Obianuju Ozoh

P

Evelyn Palmer Jonathan Palmer Padmasayee Papineni

John Park Sean Parker Edward Parkes Kate Parrott Maria Parsonage Padmavathi Parthasarathy Pujan Patel James Paton Matt Pavitt Karen Payne Donna Peat Daniel Peckham Rachel Penfold Felicity Perrin Melanie Perry Gerrard Phillips Emma Pinder Benjamin Pippard Andrew Pollard Jacqueline Pollington Aravind Ponnuswamy Sarah Popple Jessica Potter Maria Potter Helen Powell Arun Prasad Ben Probyn Poonam Puthran

Tariq Qureshi

R

Najib Rahman Crichton Ramsay Darren Ramsay Paul Ramsay Nicola Read Jennifer Rees Lee Reeves Peter Reid Louise Restrick Carl Reynolds Katie Rhatigan Pilar Rivera Ortega Cara Roberts Helen Roberts Mark Roberts Nicola Roberts Esther Robinson Polly Robinson Andrew Rosser Cris Roxas Kay Roy Hitasha Rupani Anne-Marie Russell Georgina Russell Richard J Russell Richard Russell

Q

Tim Quinnell

S

Ravijyot Saggu Anita Saigal Helen Sandilands Indrajit Sau Maeve Savage Stephen Scott James Seddon Affy Sepahzad Louise Sewell Mohammad Shadab Aqsa Shah Neeraj Shah Joanna Shakespeare Noorann Sheikh Fathimath Farah Shiham Delane Shingadia Murali Shyamsundar Mike Simmons Aran Singanayagam Sally Singh Claire Slinger Derek Sloan Nicholas Smallwood Carl Smith Daniel Smith Jaclyn Smith Laura-Jane Smith Catherine Snelson Paul Sommerfeld

Nicola Speed Elspeth Spencer Arietta Spinou Lewis Standing Andrew Stanton Chris Stevenson Matthew Steward Iain Stewart Rhianwen Stiff Carol Stonham Sandra Stych Anita Sullivan Ema Swingwood Karl Sylvester Joanna Szram

T

Nick Talbot Alison Talbot-Smith Matthew Tate Amanda Tatler Alexandra Teagle Shaun Thein Gavin Thomas Mike Thomas Roger Thompson Louise Thomson Michelle Ting Michael Toolan Athina Trachalaki

Milind Sovani

George Tsaknis Vinny Wooding Maddy Turley Angela Wright Alice Turner Lynsey Wright John Wrightson

V

Ameet Vaghela Clare Van Halsema Pamela Vaughn Ioannis Vogiatzis

Y Freda Yang Kay Por Yip

W

Paul Walker Sarah Wallace Gareth Walters Karen Ward Thomas Ward Jane Watson Nicholas Weatherley Lucy Webb Steven Welch Douglas West Jenny White Veronica White Abigail Whitehouse Elizabeth Whittaker Ruth Wiggans Meme Wijesinghe James Wildgoose Alexander Wilkinson Stephen Wilson Martin Wiselka

Appendix B

External funding/support received for annual conferences and courses.

List of Exhibitors

Sponsors for Winter Meeting 2024

Abbott Rapid Diagnostics Action Pulmonary Fibrosis Aerogen Ambu APR Medtech ACPRC ARNS ARTP Asthma+Lung UK AstraZeneca BD BALR Broncus /Uptake Medical Chiesi Cipla EU Ltd Creo Medical DC Action Erbe Fannin Fisher & Paykel GSK Guardant Health Helathcare21 Group (Aquilant) ICU Medical Inogen + Physio-Assist Insmed Inspire Sleep ILD Interdisciplinary Network It’s Interventional Kenvue LifeArc The Limbic Medtronic Mesothelioma UK MSD NRAP NIOX Healthcare Ltd NTM Patient Care UK and the NTM Network Olympus

Orion Pharma PCD Support UK PR SAS Richard Wolf Ltd Roche Rocket Medical Royal College of Speech & Language Therapists Sanofi SarcoidosisUK Stirling Anglian Thornton and Ross (STADA Group) Tidal Sense Vitalograph

Sponsors for Summer Meeting 2025

Action Pulmonary Fibrosis ARTP ACPRC ARNS AstraZeneca BD Broncus Medical Inc Chiesi Cipla Eu Ltd Consilient Health Energy Systems Catapult GSK HealthNet Homecare ICU Medical Insmed Intus Healthcare Ltd Love Medical MSD The National Aspergillosis Centre NIOX Group Pharming UK Group PRSAS Richard Wolf Ltd Roche UK Sanofi and Regeneron STADA Thornton and Ross Stirling Anglian Pharmaceuticals SWORD-THOR Vapotherm

Sponsors for Short Course Programme July 2024 to June 2025

BTS Bronchoscopy/Thoracoscopy Course 2025

AMBU Aquilant Endoscopy BD Broncus Cook Olympus Keymed Pulmonx UK Rocket Medical Richard Wolf Intuitive